化疗所致心肌病的预测与预防：能否实现？ - Suppr

Suppr

超能文献

Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?

作者信息

Granger Christopher B

出版信息

Circulation. 2006 Dec 5;114(23):2432-3. doi: 10.1161/CIRCULATIONAHA.106.666248.

DOI:10.1161/CIRCULATIONAHA.106.666248

PMID:17146002

Abstract

摘要

相似文献

Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?

Circulation. 2006 Dec 5;114(23):2432-3. doi: 10.1161/CIRCULATIONAHA.106.666248.

Anthracycline cardiotoxicity in children.

N Engl J Med. 2004 Jul 8;351(2):120-1. doi: 10.1056/NEJMp048113.

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Circulation. 2006 Dec 5;114(23):2474-81. doi: 10.1161/CIRCULATIONAHA.106.635144. Epub 2006 Nov 13.

Pharmacologic prevention of anthracycline-induced cardiomyopathy.

Cardiol Rev. 2009 Sep-Oct;17(5):243-52. doi: 10.1097/CRD.0b013e3181b8e4c8.

Exposure to anthracyclines during childhood causes cardiac injury.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019.

Strategies for reduction of anthracycline cardiac toxicity.

Semin Oncol. 1998 Oct;25(5):525-37.

Anthracycline-induced cardiomyopathy.

Postgrad Med. 2008 Nov;120(4):67-72. doi: 10.3810/pgm.2008.11.1940.

[Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].

Vopr Onkol. 2002;48(1):110-2.

Doxorubicin-induced cardiomyopathy.

N Engl J Med. 1999 Feb 25;340(8):654-5.

Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.

Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8. doi: 10.1002/pbc.20358.

引用本文的文献

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic Variants.

Int J Mol Sci. 2025 Apr 23;26(9):3966. doi: 10.3390/ijms26093966.

Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.

Lab Chip. 2024 Feb 13;24(4):869-881. doi: 10.1039/d3lc00745f.

The Imbalance of p53-Park7 Signaling Axis Induces Iron Homeostasis Dysfunction in Doxorubicin-Challenged Cardiomyocytes.

Adv Sci (Weinh). 2023 May;10(15):e2206007. doi: 10.1002/advs.202206007. Epub 2023 Mar 26.

RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.

Cell Stem Cell. 2021 Dec 2;28(12):2076-2089.e7. doi: 10.1016/j.stem.2021.08.006. Epub 2021 Sep 15.

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis.

J Clin Med. 2021 Aug 22;10(16):3731. doi: 10.3390/jcm10163731.

Cardiovascular and Cancer Risk: The Role of Cardio-oncology.

J Adv Pract Oncol. 2018 Mar;9(2):160-176. Epub 2018 Mar 1.

Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

J Nucl Cardiol. 2019 Aug;26(4):1327-1344. doi: 10.1007/s12350-018-1190-2. Epub 2018 Feb 1.

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Nat Med. 2016 May;22(5):547-56. doi: 10.1038/nm.4087. Epub 2016 Apr 18.

Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.

Prog Pediatr Cardiol. 2014 Dec 1;37(1-2):23-27. doi: 10.1016/j.ppedcard.2014.10.006.

Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor.

PLoS One. 2013 Oct 17;8(10):e77713. doi: 10.1371/journal.pone.0077713. eCollection 2013.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验